Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Univariate analysis of C3a, C4a and C5a plasma levels in nAMD patients with CNV, RAP and PCV

From: Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration

Variables (ng/ml)

Controls (mean ± SD)

CNV (mean ± SD)

RAP (mean ± SD)

PCV (mean ± SD)

P value controls vs CNV vs RAP vs PCVa

P value

Bonferroni post hoc test

n = 43

n = 61

n = 17

n = 14

C3a

11.95 ± 3.30

15.29 ± 4.29

14.15 ± 5.93

12.55 ± 2.86

<0.001

<0.001 b

0.609c

1.000d

C4a

68.91 ± 33.23

118.16 ± 93.41

84.73 ± 55.07

96.51 ± 63.71

0.004

0.003 b

1.000c

1.000d

C5a

8.34 ± 2.05

9.92 ± 2.81

8.10 ± 2.53

8.68 ± 1.95

0.016

0.044 b

1.000c

1.000d

  1. aOne-way ANOVA
  2. bControls vs CNV
  3. cControls vs RAP
  4. dControls vs PCV
  5. Bold P < 0.05
  6. SD standard deviation
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us